The invention primarily relates to fastening and stabilizing tissues, implants, and/or bondable materials, such as the fastening of a tissue and/or implant to a bondable material, the fastening of an implant to tissue, and/or the fastening of an implant to another implant. This may involve using an energy source to bond and/or mechanically to stabilize a tissue, an implant, a bondable material, and/or other biocompatible material. The invention may also relate to the use of an energy source to remove and/or install an implant and/or bondable material or to facilitate solidification and/or polymerization of bondable material.

The invention primarily relates to fastening and stabilizing tissues, implants, and/or bondable materials, such as the fastening of a tissue and/or implant to a bondable material, the fastening of an implant to tissue, and/or the fastening of an implant to another implant. This may involve using an energy source to bond and/or mechanically to stabilize a tissue, an implant, a bondable material, and/or other biocompatible material. The invention may also relate to the use of an energy source to remove and/or install an implant and/or bondable material or to facilitate solidification and/or polymerization of bondable material.

The present disclosure pertains to the field of biomedical materials, and in particular relates to a medical hydrogel, a preparation method and uses thereof, and a kit for preparing the medical hydrogel. The medical hydrogel of the present disclosure comprises a hydrogel skeleton, and a chelating agent chelated to the hydrogel skeleton; wherein the hydrogel skeleton comprises a polymer that is formed by the bonding of a polyethylene glycol derivative I having a structure shown in Formula (I) and a polyethylene glycol derivative II having a structure shown in Formula (II) and has multiple “long arms”. After tannic acid and/or citric acid as a chelating agent chelates with the hydrogel skeleton, a medical hydrogel can be obtained, which has good bacteriostatic properties, mechanical properties, adhesion properties, low swelling properties, and controllable gel formation rate and degradation rate. Moreover, the hydrogel is able to maintain viscosity in a wet state without being affected by body fluids, and it can still ensure effective adhesion and closure of wounds if there is movement or pulsation of the tissue, thus having great clinical application prospects.

The present disclosure pertains to the field of biomedical materials, and in particular relates to a medical hydrogel, a preparation method and uses thereof, and a kit for preparing the medical hydrogel. The medical hydrogel of the present disclosure comprises a hydrogel skeleton, and a chelating agent chelated to the hydrogel skeleton; wherein the hydrogel skeleton comprises a polymer that is formed by the bonding of a polyethylene glycol derivative I having a structure shown in Formula (I) and a polyethylene glycol derivative II having a structure shown in Formula (II) and has multiple “long arms”. After tannic acid and/or citric acid as a chelating agent chelates with the hydrogel skeleton, a medical hydrogel can be obtained, which has good bacteriostatic properties, mechanical properties, adhesion properties, low swelling properties, and controllable gel formation rate and degradation rate. Moreover, the hydrogel is able to maintain viscosity in a wet state without being affected by body fluids, and it can still ensure effective adhesion and closure of wounds if there is movement or pulsation of the tissue, thus having great clinical application prospects.

A tissue adhesive for contacting a tissue site, the tissue adhesive comprising: a mixture of natural polymers; and an activating agent enhancing the adhesive properties of the mixture of natural polymers. And a tissue adhesive for contacting a tissue site, the tissue adhesive comprising: a mixture of natural polymers; and an aqueous solution of a water soluble starch or a water soluble starch derivative which forms a gel with the addition of the mixture of natural polymers.

The present invention relates to a haemostatic powder comprising at least 10 wt. % of particle agglomerates, said particle agglomerates having a diameter in the range of 1-500 μm and comprising: electrophilic polyoxazoline particles containing electrophilic polyoxazoline carrying at least 3 reactive electrophilic groups that are capable of reacting with amine groups in blood under the formation of a covalent bond; and nucleophilic polymer particles containing a water-soluble nucleophilic polymer carrying at least 3 reactive nucleophilic groups that, in the presence of water, are capable of reacting with the reactive electrophilic groups of the electrophilic polyoxazoline under the formation of a covalent bond between the electrophilic polyoxazoline and the nucleophilic polymer.

When applied to a bleeding site, the haemostatic powder of the present invention turns into a gel while at the same time binding to proteins present in the blood and on the surrounding tissue.

Adhesive compositions exhibiting antimicrobial properties, good stability, long shelf lives and enhanced release of antimicrobial agents are described. In certain versions, the compositions also exhibit relatively high fluid handling capacities. The adhesive compositions inhibit microbial growth by more than 2 log after 24 hours contact and particularly more than 3.5 log after 6 hours contact. Also described are various medical articles using such adhesives and related methods.

Coated and expanded, nanofiber structures are provided and methods of use thereof.

A sealant for sealing a puncture through tissue includes a first section. e.g., formed from freeze-dried hydrogel, and a second section extending from the distal end. The second section may be formed from PEG-precursors including PEG-ester and PEG-amine, e.g., in an equivalent ratio of active group sites of PEG-ester/PEG-amine greater than one-to-one, e.g., such that excess esters may provide faster activation upon contact with physiological fluids and enhance adhesion of the sealant within a puncture. At least some of the precursors remain in an unreactive state until exposed to an aqueous physiological environment, e.g., within a puncture, whereupon the precursors undergo in-situ cross-linking to provide adhesion to tissue adjacent the puncture. For example, the PEG-amine precursors may include the free amine form and the salt form. The free amine form at least partially cross-links with the PEG-ester and the salt form remains in the unreactive state in the sealant before introduction into the puncture.

A sealant for sealing a puncture through tissue includes a first section. e.g., formed from freeze-dried hydrogel, and a second section extending from the distal end. The second section may be formed from PEG-precursors including PEG-ester and PEG-amine, e.g., in an equivalent ratio of active group sites of PEG-ester/PEG-amine greater than one-to-one, e.g., such that excess esters may provide faster activation upon contact with physiological fluids and enhance adhesion of the sealant within a puncture. At least some of the precursors remain in an unreactive state until exposed to an aqueous physiological environment, e.g., within a puncture, whereupon the precursors undergo in-situ cross-linking to provide adhesion to tissue adjacent the puncture. For example, the PEG-amine precursors may include the free amine form and the salt form. The free amine form at least partially cross-links with the PEG-ester and the salt form remains in the unreactive state in the sealant before introduction into the puncture.